Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
Myo-Inositol- Based Co-treatment in Women With PCOS Undergoing Assisted Reproductive Technology
This is a prospective comparative randomized controlled study investigating the effect of
 Myo-Inositol-based co-treatment on oocyte quality measures in women with PCOS.
Polycystic Ovary Syndrome is the most common cause of chronic anovulation in women. Women
 with PCOS undergoing IVF are at an increased risk for developing both multiple gestation and
 ovarian hyperstimulation syndrome (OHSS). Since insulin resistance and hyperinsulinemia have
 been implicated in the pathophysiology of the disorder, the administration of metformin
 before or during an IVF cycle has been practiced for years in an attempt to improve
 follicular parameters necessary for reproductive success. Recently, a growing body of
 evidence has implicated alternative insulin sensitizing drugs, namely Myo-Inositol, in
 improving various manifestations of the disorder in this women population. Little has been
 done to evaluate the effect of Myo-Inositol co-treatment on the reproductive performance of
 PCOS women undergoing Assisted Reproductive Technologies (ART). In this prospective
 comparative randomized controlled study, women will be randomized into two groups: Women in
 the control group will receive folic acid daily. Women in the study group will receive
 Myo-Inositol, in combination with alpha- lipoic acid and cysteine, per day plus folic acid
 supplemented daily along with ovarian stimulation.
Inclusion Criteria:

 -  Age 18-40 years at the time of enrollment.

 -  Women diagnosed with PCOS according to the Rotterdam criteria indicated by
 oligoamenorrhea (six or fewer menstrual cycles during a period of 1 year),
 hyperandrogenism (hirsutism, acne, or alopecia) or hyperandrogenemia (elevated levels
 of total or free T) and typical features of ovaries on ultrasound scan.

 -  Planned IVF/ICSI treatment.

 -  Normal uterine cavity (as assessed by hysteroscopy or HSG).

 -  Normal hormonal investigation: TSH and PRL.

 Exclusion Criteria:

 -  Azoospermia.

 -  Other medical conditions causing ovulatory disorders, such as hyperprolactinemia,
 hypothyroidism, or adrenal hyperplasia.

 -  Hypersensitivity to Myo-Inositol or its derivatives.